Skip to content

    Camlin Fine

    CAMLINFINEGood
    Chemicals·10 Nov 2025
    Management Summary

    Camlin Fine Sciences delivered a strong Q2 FY26, with revenue growing 8.6% sequentially to ₹460 crores, driven by volume increases in both straights and blends. EBITDA saw a substantial recovery to ₹33 crores, achieving a 7.27% margin, supported by optimal plant utilization. While Vanillin volumes rose, realizations faced pressure from tariffs and channel destocking, which is projected to clear by Q4 FY26 in the US and Q1 FY27 in Europe. The company remains on track for its full-year revenue guidance and anticipates further growth from its Blends segment and the upcoming Vinpai acquisition.

    Highlights

    8

    • Revenue of ₹460 crores, up 8.6% QoQ.

    • EBITDA at ₹33 crores, a significant increase from ₹19 crores QoQ.

    • EBITDA Margin stood at 7.27% for the quarter.

    • Gross Margin improved to 46% in Q2 FY26, up from 43-44% in Q1 FY26.

    • Blends business grew 8% QoQ, targeting 18-20% YoY growth.

    • Vanillin volumes increased 35% QoQ, with a FY26 target of 2,500 tons and FY27 target of 4,000 tons.

    • Net Debt reported at ₹520 crores.

    • Vinpai integration expected by end of November 2025, consolidating from Q2 FY26.

    Concerns

    3

    • Tariff pressure on Vanillin exports to US

    • Channel inventory overhang for Vanillin in US and Europe

    • China dumping of Vanillin in non-US/Europe markets

    What Changed3

    vs Q3 FY26

    Guidance items7 → 12 (+5)Risks discussed4 → 6 (+2)Q&A highlights8 → 3 (-5)

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue₹460 Cr+8.6%QoQ
    2. 02EBITDA₹33 Cr+73.7%QoQ
    3. 03EBITDA Margin7.3%
    4. 04Gross Margin46%
    5. 05Net Debt₹520 Cr

    Segment breakdown

    Blends
    8% Revenue Growth
    Aroma (Vanillin)
    35% Volume Growth11 $/kg Realization
    Straights (TBHQ, BHA)
    40% Volume Growth
    List

    Guidance & targets

    12
    CategoryTargetPriority
    Revenue
    Total Sales
    ₹2,000-2,100 crores
    		High
    Volume
    Vanillin Sales
    2,500 tons
    		High
    Volume
    Vanillin Sales
    4,000 tons
    		High
    Growth
    Blends Business Growth
    18-20%
    		High
    Growth
    Blends Business Growth
    20%
    		High
    Headcount
    Employee Cost
    small, some percentage increase
    		Medium
    Other
    Vinpai Integration
    by November end
    		High
    Profitability
    European Discontinued Business Loss
    ₹25 crores
    		High
    Profitability
    European Discontinued Business Loss
    ₹2 crores per quarter
    		High
    Profitability
    China Discontinued Business Cost
    ₹1 crore
    		High
    Profitability
    China Discontinued Business Cost
    No cost
    		High
    Capacity
    Diphenol Facility Full Capacity Cost
    $8
    		High

    Risks & concerns

    7
    RiskSeverity

    Tariff pressure on Vanillin exports to US

    50% tariff levied on Indian exports to US is putting pressure on Vanillin realization. — Management acknowledged

    high

    Local competition in India for TBHQ, BHA

    Heightened local competition is causing realization pressure in the straights business. — Management acknowledged

    medium

    Channel inventory overhang for Vanillin in US and Europe

    Destocking in the US is expected by Q4 FY26, and in Europe by Q1 FY27, impacting current demand and realization. — Management acknowledged

    high

    Slowdown in US pet food business

    Slowdown in the last two quarters, but now seems to be improving and picking up again. — Management downplayed

    medium

    China dumping of Vanillin in non-US/Europe markets

    Chinese competitors are selling Vanillin at very low prices ($7-$7.5) in these markets, making it difficult to compete. — Management acknowledged

    high

    Syensqo restarting synthetic Vanillin unit in France

    Management believes there is still a 3,500-ton market gap in Europe that they can fill despite Syensqo's 5,000-ton capacity. — Analyst downplayed

    low

    Areas of Evasion(1)

    • maximum outward contract signed

    Q&A highlights

    3

    “The de-stocking in the US is expected to be completed by Q4 of this year. And in Europe, it is expected to be cleared by Q1 of FY'27. Because Europe, the anti-dumping duty was levied only in July. So there was a large amount of channel stocks lying in Europe.”

    Clarifies the extended timeline for a key demand headwind, indicating when market conditions might normalize for Vanillin, and explains the reason for the delay in Europe.

    asked by Rehan

    2 min read6 chapters

    Detailed Narrative

    01

    Q2 FY26 Financial Performance Overview

    Camlin Fine Sciences reported a robust Q2 FY26 with revenue reaching ₹460 crores, marking an 8.6% sequential growth. The company's EBITDA saw a significant improvement, climbing to ₹33 crores (7.27% margin) from ₹19 crores in the previous quarter. Gross margins also expanded to 46% in Q2 FY26, up from 43-44% in Q1 FY26, attributed to optimal capacity utilization at its Tarapur and Dahej plants.

    02

    Segmental Growth and Realization Pressures

    The Blends business demonstrated strong sequential growth of 8% and is targeted for 18-20% YoY growth. Vanillin volumes increased by 35% QoQ, but net realizations remained subdued at $11-12 per unit due to a 50% tariff on Indian exports to the US and existing channel inventory. The Straights business (TBHQ, BHA) also saw a 40% QoQ volume increase, despite facing realization pressure from heightened local competition in India.

    03

    Vanillin Market Dynamics and Destocking Timeline

    The company is navigating a challenging Vanillin market characterized by significant channel inventory in the US and Europe. Management expects destocking in the US to conclude by Q4 FY26, while Europe's inventory is projected to clear by Q1 FY27, a slight delay from previous estimates. Despite these headwinds, the company is targeting Vanillin sales of 2,500 tons for FY26 and an ambitious 4,000 tons for FY27, leveraging its current 50-55% capacity utilization.

    04

    Strategic Acquisitions and Capacity Utilization

    The integration of Vinpai, a new acquisition in France, is anticipated by the end of November 2025, with consolidation expected to begin in Q2 FY26, contributing additional revenue. The Diphenol facility is currently operating at 50-55% utilization, producing around 700 metric tons against an annual capacity of 6,000 metric tons. Management noted that current production costs are $9.5-10 per unit, which is expected to decrease to $8 per unit at full capacity.

    05

    Discontinued Operations and Future Profitability

    Camlin Fine Sciences provided clear timelines for the reduction of losses from its discontinued operations. The European diphenol plant, which was mothballed, is expected to incur approximately ₹25 crores in losses for FY26, projected to significantly reduce to ₹2 crores per quarter from FY27 onwards. Similarly, the discontinued China business, currently incurring about ₹1 crore in costs, is expected to have no cost impact from FY27 following liquidation proceedings.

    06

    Outlook and Growth Drivers

    The company reiterated its full-year revenue guidance of ₹2,000-2,100 crores. Key growth drivers for the next fiscal year include a target of 4,000 tons for Vanillin sales and a 20% growth in the Blends business. Management is also expanding its field force by approximately 21% (31 people added this quarter) to support the Blends segment's growth, with the impact expected to be visible from Q4 FY26 and Q1 FY27.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.